DIADIA1.85%
SPYSPY1.51%
QQQQQQ1.90%
Trending
Top trending tickerORCLORCL12.39%
DJTDJT4.53%
SMCISMCI27.76%
TSLATSLA3.64%
QQQQQQ1.90%
RIVNRIVN5.91%
GLDGLD4.39%
CASYCASY20.29%
FRMIFRMI19.04%
RTXRTX2.29%
Top trending tickerORCLORCL12.39%
DJTDJT4.53%
SMCISMCI27.76%
TSLATSLA3.64%
QQQQQQ1.90%
RIVNRIVN5.91%
GLDGLD4.39%
CASYCASY20.29%
FRMIFRMI19.04%
RTXRTX2.29%
homeSymbolTTRXnews
TTRX logo

TTRXTurn Therapeutics Inc

$5.42
$0.475
(9.40%)
Today
Closed $5.53
$0.11
(1.99%)
After Hours
Updated: 06:43 PM EDT
EarningsAug 13
Mkt Cap$150.58M
Vol61,129.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

News
all
press releases
Turn Therapeutics Reports Interim Analysis Findings and Adaptive Optimization Strategy from Phase 2 GX-03 Trial in Moderate-to-Severe Atopic Dermatitis
Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, localized therapies for inflammatory skin diseases, today announced interim analysis findings from the first 50 completed subjects enrolled in its ongoing randomized, double-blind, vehicle-controlled...
Business Wire
News Placeholder
More News
News Placeholder
Turn Therapeutics Announces Peer-Reviewed Publication in Journal of Dermatological Treatment Highlighting GX-03 Activity in IL-36 Associated Inflammatory Model
Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company focused on developing localized therapies for inflammatory and infectious skin diseases, today announced the publication of a peer-reviewed research article in the Journal of Dermatological Treatment evaluating the...
Business Wire
News Placeholder
Turn Therapeutics to Present at Jefferies Global Healthcare Conference 2026
Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, localized therapies for inflammatory skin diseases, today announced that Bradley Burnam, Chief...
Business Wire
News Placeholder
Turn Therapeutics Appoints Physician-Scientist and Former FDA Commissioner, Dr. Stephen M. Hahn, as Executive Clinical and Regulatory Lead
Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, localized therapies for inflammatory skin diseases, today announced the appointment of Stephen M...
Business Wire
News Placeholder
Turn Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunological therapies for dermatologic conditions, today reported financial...
Business Wire
News Placeholder
Turn Therapeutics (NASDAQ:TTRX) Trading 6% Higher - Should You Buy?
Turn Therapeutics (NASDAQ:TTRX) Shares Up 6% - Here's Why...
MarketBeat
News Placeholder
Turn Therapeutics (NASDAQ:TTRX) Issues Earnings Results
Turn Therapeutics (NASDAQ:TTRX - Get Free Report) announced its quarterly earnings data on Tuesday. The company reported ($0.09) EPS for the quarter...
MarketBeat
News Placeholder
Turn Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates
Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunology therapies for dermatologic conditions, today reported financial results...
Business Wire
News Placeholder
D. Boral Capital Reaffirms Buy Rating for Turn Therapeutics (NASDAQ:TTRX)
D. Boral Capital restated a "buy" rating and issued a $8.00 price objective on shares of Turn Therapeutics in a research note on Tuesday...
MarketBeat
News Placeholder
Turn Therapeutics Secures Up to $25 Million in Financing From Avenue Capital Group
Turn Therapeutics, Inc. (Nasdaq: TTRX), a clinical-stage dermatology company developing novel therapies for inflammatory skin diseases, today announced it has entered into a growth capital loan...
Business Wire
<
1
2
...
>

Advertisement|Remove ads.

Advertisement|Remove ads.